# OnCo record tigit (target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/targets/tigit/>
  a schema:BioChemEntity ;
  onco:kind "target" ;
  schema:identifier "tigit" ;
  schema:name "TIGIT"@en ;
  schema:description "TIGIT is an inhibitory receptor on T and natural killer cells that binds PVR (CD155) on tumour cells, so blocking it was expected to amplify PD-1 and PD-L1 inhibitors. Tiragolumab, domvanalimab and others then failed to add benefit in phase 3 lung cancer trials despite encouraging phase 2 signals, and the lack of a TIGIT-specific biomarker remains a weakness."@en ;
  schema:url <https://onco.cc/targets/tigit/> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/TIGIT>, <https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:26838>, <https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000181847>, <https://www.uniprot.org/uniprotkb/Q495A1/entry>, <https://www.ncbi.nlm.nih.gov/gene/201633> ;
  owl:sameAs <http://www.wikidata.org/entity/Q21114021> ;
  schema:citation <https://en.wikipedia.org/wiki/TIGIT> ;
  onco:tag "checkpoint", "failed-so-far" ;
  schema:alternateName "TIGIT" ;
  onco:targetClass "checkpoint" ;
  onco:firstDescribed "2004"^^xsd:gYear ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/sclc/> ;
  onco:technologies <https://onco.cc/technologies/tigit-blockade/> ;
  onco:drugs <https://onco.cc/drugs/rilvegostomig/>, <https://onco.cc/drugs/hb0036/> ;
  onco:pathways <https://onco.cc/pathways/pd1-checkpoint/>, <https://onco.cc/pathways/t-cell-exhaustion/> .